In partnership with
No new safety signals in ofatumumab open-label data
Low-dose rituximab as effective as high-dose, but safer
Induction more effective than escalation as strategy in RRMS
Management of PPMS and SPMS with approved DMT
Amantadine, modafinil, and methylphenidate for MS-related fatigue
Predictive value of neurodegenerative CSF markers in MS
Masitinib possible new treatment of progressive MS
Gender-based approach to MS therapeutics: a missed opportunity
Eculizumab reduces long-term relapse risk in AQP4+ NMOSD
Cardiovascular risk factors linked to brain atrophy in younger MS patients
Gold nanocrystals may improve brain metabolic profile
Functional potential of gut microbiome in paediatric MS
MS patients have no increased risk of contracting COVID-19
EDSS and age are risk factors for severe COVID-19 in MS patients
Anti-CD20 mAbs associated with worse COVID-19 outcomes
Brain alterations at onset of first demyelinating event
Interrupting DMT due to pregnancy increases NfL levels in MS
NG-specific biomarkers can quickly differentiate NMOSD from MS
Top image: @ iStockPhoto: wildpixel
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP